Category

ECM

Daily Brief ECM: Mao Geping Cosmetics Pre-IPO – Riding on the Founder’s Reputation and more

By | Daily Briefs, ECM

In today’s briefing:

  • Mao Geping Cosmetics Pre-IPO – Riding on the Founder’s Reputation
  • QuantumPharm IPO Trading – Lukewarm Insti Demand Combined with a Tight Float at Listing
  • Medtide Pre-IPO Tearsheet
  • Telix Pharmaceutical US ADS – Momentum Remains Strong, Offering Would Triple Its Cash Base


Mao Geping Cosmetics Pre-IPO – Riding on the Founder’s Reputation

By Sumeet Singh

  • Mao Geping Cosmetics is looking to raise around US$300m in its upcoming Hong Kong IPO.
  • Mao Geping Cosmetics (MGC) operates in the premium beauty segment. Operating via its two brands, MAOGEPING and Love Keeps, MGC offers a wide range of color cosmetics and skincare products.
  • In this note, we look at the company’s past performance.

QuantumPharm IPO Trading – Lukewarm Insti Demand Combined with a Tight Float at Listing

By Clarence Chu

  • QuantumPharm (QUP HK) raised US$126m from its Hong Kong IPO.
  • QuantumPharm is a R&D platform, utilizing quantum physics-based first-principles calculation, advanced AI, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&D solutions.
  • We have covered various aspects of the deal in our previous note. In this note, we will talk about the demand and trading dynamics.

Medtide Pre-IPO Tearsheet

By Ethan Aw

  • Medtide (1268709D CH) is looking to raise at least US$100m in its upcoming HK IPO. The deal will be run by Morgan Stanley and Citic Securities.
  • Medtide is the third largest peptide-focused contract research, development and manufacturing organization (CRDMO) worldwide in terms of sales revenue in 2023, according to F&S. 
  • Its full-cycle services range from early-stage discovery, pre-clinical research and clinical development to commercial-stage production.

Telix Pharmaceutical US ADS – Momentum Remains Strong, Offering Would Triple Its Cash Base

By Clarence Chu

  • Telix Pharmaceuticals (TLX AU) is looking to raise around US$190m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
  • TLX is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
  • In this note, we talk about the updates since our last note and current deal dynamics.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Atour Lifestyle Holdings Placement – Well Flagged Deal and more

By | Daily Briefs, ECM

In today’s briefing:

  • Atour Lifestyle Holdings Placement – Well Flagged Deal, past Selldowns Have Done Well
  • New Gonow Recreational Vehicles Pre-IPO Tearsheet
  • Sanstar IPO- Forensic Analysis


Atour Lifestyle Holdings Placement – Well Flagged Deal, past Selldowns Have Done Well

By Sumeet Singh

  • Legend Capital (LC), one of the principal shareholders of Atour Lifestyle Holdings (ATAT US), is looking to raise around US$168m through a secondary selldown.
  • This will be the third selldown by Legend Capital in just over a year’s time. Hence, the deal is well flagged.
  • In this note, we will talk about the placement and run the deal through our ECM framework.

New Gonow Recreational Vehicles Pre-IPO Tearsheet

By Clarence Chu

  • New Gonow Recreational Vehicles (NGRV HK) is looking to raise US$100m in its upcoming Hong Kong IPO. The bookrunner on the deal is Huatai International.
  • New Gonow Recreational Vehicles (NGRV) is a recreational vehicle (RV) platform with an extensive presence in Australasia that designs, develops, manufactures and sells bespoke towable RVs.
  • According to Frost & Sullivan (F&S), the firm held the second-largest market share in Australasia’s RV industry in terms of 2023 sales volume.

Sanstar IPO- Forensic Analysis

By Nitin Mangal

  • Sanstar (SANSTAR123 IN) is primarily focused in producing maize based specialty products and ingredient solutions in India. It currently occupies a market share of around 7.8%. 
  • The company has shown good growth in the last two years; however, when it comes to accounting and forensic checks there are several grey areas/unique policies.
  • Examples: Revenues are stated gross of GST and are net of freight and brokerage costs. Classification of some of free reserves into revaluation reserve, Salaries paid to some senior personnel,etc.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Guzman Y Gomez IPO – Peer Comp and Thoughts on Valuations and more

By | Daily Briefs, ECM

In today’s briefing:

  • Guzman Y Gomez IPO – Peer Comp and Thoughts on Valuations
  • Lalatech IPO: Using YMM:US as Main Comp, Equity Valuation of US$11-12 Bn (Or More) Justifiable
  • Minieye Technology Pre-IPO Tearsheet


Guzman Y Gomez IPO – Peer Comp and Thoughts on Valuations

By Sumeet Singh

  • Guzman Y Gomez (GYG) now plans to raise US$221m, an increase from its earlier target of US$160m, in its Australian IPO.
  • GYG is a quick service restaurant business with more than 200 restaurants globally. It mainly focuses on fresh, made-to-order, Mexican-inspired food.
  • We have looked at the company’s performance in our past notes. In this note, we talk about valuations.

Lalatech IPO: Using YMM:US as Main Comp, Equity Valuation of US$11-12 Bn (Or More) Justifiable

By Daniel Hellberg

  • Based on returns and margins, US-listed Full Truck Alliance is best comp
  • Lalatech probably deserves premium valuation multiples vs Full Truck Alliance 
  • An equity valuation of US$11bn+ justifiable; will investors look at recent flops?

Minieye Technology Pre-IPO Tearsheet

By Clarence Chu

  • Minieye Technology (1426169D CH) is looking to raise US$150m in its upcoming Hong Kong IPO. The bookrunners on the deal are Citic Securities and CICC.
  • Minieye Technology (Minieye) is an intelligent driving and cabin solutions provider in China, offering solutions for critical aspects of the driving experience, including piloting, parking and in-cabin functions.
  • Providing Level 0-Level 2++ intelligent driving solutions that are full-stack in-house developed and proven by mass production, the firm has also been developing advanced Level 4 autonomous driving technologies.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: SF Holding Pre-IPO: FY23 and more

By | Daily Briefs, ECM

In today’s briefing:

  • SF Holding Pre-IPO: FY23, Q124 Results Reviewed | Sales Mix Impacts | Recent Monthly Revenue Trend
  • ECM Weekly (10th June 2024) – Webtoon, Shift Up, QuantumPharm, Guzman, Kakaopay, Telix, Yankuang


SF Holding Pre-IPO: FY23, Q124 Results Reviewed | Sales Mix Impacts | Recent Monthly Revenue Trend

By Daniel Hellberg

  • In this insight we cover recent earnings results, revenue mix, YTD trends
  • Fluctuating performance of its international segment impacted FY23 and Q124
  • Improving international segment could boost overall momentum in Q2-Q4 2024

ECM Weekly (10th June 2024) – Webtoon, Shift Up, QuantumPharm, Guzman, Kakaopay, Telix, Yankuang

By Sumeet Singh


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Tempus AI IPO: AI in Diagnostics at Scale and more

By | Daily Briefs, ECM

In today’s briefing:

  • Tempus AI IPO: AI in Diagnostics at Scale, Investor Sentiment Appears Positive


Tempus AI IPO: AI in Diagnostics at Scale, Investor Sentiment Appears Positive

By Andrei Zakharov

  • Tempus AI, a healthcare IT company and provider of next-gen diagnostics, is expected to IPO next week. The company plans to raise $411M at the high end of the range.
  • The most recent S-1/A puts the expected price range per share at $35 to $37, implying a market cap of ~$6B at the midpoint.
  • Tempus AI provides personalized cancer care and brings AI to healthcare at scale. They train LLMs to develop AI applications and have the largest public genomic data sets in oncology

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Initial Thoughts on the Yanolja IPO and more

By | Daily Briefs, ECM

In today’s briefing:

  • Initial Thoughts on the Yanolja IPO


Initial Thoughts on the Yanolja IPO

By Douglas Kim

  • Yanolja is getting ready to complete its IPO in the US in the next several months. Softbank invested about US$1.7 billion in Yanolja in 2021.
  • The valuation of Yanolja could be between US$7 billion to US$9 billion. The company could raise nearly US$400 million in this IPO. 
  • Overall, we are concerned about the valuations of Yanolja if indeed the bankers push ahead with the IPO at the valuation range of US$7 billion to US$9 billion.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: What Did FSS Point Out to Shift Up? & What Impact Would It Have on Bookbuilding Sentiment? and more

By | Daily Briefs, ECM

In today’s briefing:

  • What Did FSS Point Out to Shift Up? & What Impact Would It Have on Bookbuilding Sentiment?
  • Guzman Y Gomez IPO – The Positives – Network Growing, Sales Have Outpaced Network Growth
  • QuantumPharm IPO – Most of the Potential Has Already Been Baked In
  • Guzman Y Gomez IPO – The Negatives – Lawsuits and Management Churn


What Did FSS Point Out to Shift Up? & What Impact Would It Have on Bookbuilding Sentiment?

By Sanghyun Park

  • FSS wants Nikke’s MAU data to address revenue concerns. They also seek April and May sales data for Stellar Blade to address valuation concerns despite its recent launch.
  • Shift Up updated the prospectus with Nikke’s increasing MAU data but didn’t include Stellar Blade sales data. FSS may request further revisions, possibly delaying the IPO again.
  • Nikke’s MAU has risen but plateaued versus the previous quarter, and uncertainty surrounds Stellar Blade’s April-May sales, potentially impacting IPO pricing.

Guzman Y Gomez IPO – The Positives – Network Growing, Sales Have Outpaced Network Growth

By Sumeet Singh

  • Guzman Y Gomez plans to raise around US$160m in its Australian IPO.
  • GYG is a quick service restaurant business with more than 200 restaurants globally. It mainly focuses on fresh, made-to-order, Mexican-inspired food.
  • In this note, we look at the company’s prior performance and future prospects.

QuantumPharm IPO – Most of the Potential Has Already Been Baked In

By Clarence Chu

  • QuantumPharm (QUP HK) is looking to raise US$144m from its Hong Kong IPO.
  • QuantumPharm is a R&D platform, utilizing quantum physics-based first-principles calculation, advanced AI, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&D solutions.
  • In our previous notes, we looked at the firm’s past performance and PHIP updates. In this note, we share our thoughts on valuations. 

Guzman Y Gomez IPO – The Negatives – Lawsuits and Management Churn

By Sumeet Singh

  • Guzman Y Gomez plans to raise around US$160m in its Australian IPO.
  • GYG is a quick service restaurant business with more than 200 restaurants globally. It mainly focuses on fresh, made-to-order, Mexican-inspired food.
  • In this note, we talk about the not-so-positive aspects of the deal.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Shift Up Delays the IPO and Stellar Blade Tops Number One Game in the US in April and more

By | Daily Briefs, ECM

In today’s briefing:

  • Shift Up Delays the IPO and Stellar Blade Tops Number One Game in the US in April
  • Sakura Internet Placement – Beneficiary of the AI-Wave Looking to Double Down
  • Webtoon Entertainment Pre-IPO – The Positives – Just Turned Profitable
  • Pre-IPO Midea Group H Share – Even in the Face of Challenges, There Is Still Investment Value
  • Webtoon Entertainment Pre-IPO – The Negatives – Korea Revenue Declined, JP Acquisition to the Rescue


Shift Up Delays the IPO and Stellar Blade Tops Number One Game in the US in April

By Douglas Kim

  • On 5 June, Shift Up announced that it will be postponing its IPO to July. The original book building period for the institutional investors was from 3 to 13 June.  
  • The final book building date has been postponed to 27 June. The subsequent public offering subscription for general investors was also postponed to 2 to 3 July.
  • A major investment positive of Shift Up is enormous initial success of Stellar Blade which was the best selling game in the U.S. and numerous other countries in April 2024.

Sakura Internet Placement – Beneficiary of the AI-Wave Looking to Double Down

By Clarence Chu

  • Sakura internet (3778 JP) is looking to raise US$127m from its primary follow-on. Proceeds will be used towards purchasing GPU servers, and constructing new data center facilities.
  • While 11% of total shares outstanding are offered here, the deal would be easily digested by the market, representing just 0.8 days of its three month ADV.
  • In this note, we run the deal through our ECM framework and comment on deal dynamics.

Webtoon Entertainment Pre-IPO – The Positives – Just Turned Profitable

By Ethan Aw

  • Webtoon Entertainment (WBTN US) is looking to raise up to US$500m in its US IPO.
  • Webtoon Entertainment is a global storytelling platform where a community of creators and users discover, create and share new content. 
  • In this note, we talk about the positive aspects of the deal.

Pre-IPO Midea Group H Share – Even in the Face of Challenges, There Is Still Investment Value

By Xinyao (Criss) Wang

  • Although Midea’s performance keeps growing, it is difficult for the home appliance industry to return to rapidly growing incremental market as it was during the robust development of real estate.
  • As Midea’s To C business encounters growth bottleneck, To B business has become new performance driver and second growth curve, but several new businesses are facing challenges in 24Q1.
  • For mature leading enterprises in home appliance industry, a valuation of 10-20x PE is reasonable, which means market value of RMB370-740 billion, assuming 2024 net profit would reach RMB37 billion.

Webtoon Entertainment Pre-IPO – The Negatives – Korea Revenue Declined, JP Acquisition to the Rescue

By Ethan Aw

  • Webtoon Entertainment (WBTN US) is looking to raise up to US$500m in its US IPO.
  • Webtoon Entertainment is a global storytelling platform where a community of creators and users discover, create and share new content.
  • In this note, we talk about the not-so-positive aspects of the deal.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: MMG (1208 HK) – $1.1bn+ Rights Offering – Expect Regular Rights Trading Dynamics and more

By | Daily Briefs, ECM

In today’s briefing:

  • MMG (1208 HK) – $1.1bn+ Rights Offering – Expect Regular Rights Trading Dynamics
  • MMG (1208 HK): US$1.2bn Highly Dilutive Rights Issue
  • Raspberry Pi IPO Valuation Analysis


MMG (1208 HK) – $1.1bn+ Rights Offering – Expect Regular Rights Trading Dynamics

By Travis Lundy

  • Mmg Ltd (1208 HK) today announced a 2:5 Rights Offering to raise US$1.15bn at HK$2.62/share in order to pay down debt from their recent Botswanan copper mine acquisition. 
  • It was a sizeable acquisition, and the near-term EV/EBITDA of the acquisition is 10x or above. The longer-term EV/EBITDA is in the 3s based on expansion later this decade.
  • The Rights Offering is underwritten, supported by its 67.5% owner. SOUTHBOUND holds 10+%. There are short dynamics, arb dynamics, “don’t wanna spend more” dynamics. There’s a path here.

MMG (1208 HK): US$1.2bn Highly Dilutive Rights Issue

By Arun George

  • Mmg Ltd (1208 HK) will raise HK$9.1bn (US$1.2bn) through 2 rights shares for every 5 existing shares rights offering. The rights price is HK$2.62, a 24.7% discount to the TERP.
  • The rights proceeds will be used to repay existing debt, which will allow it to use other funds to better support the ongoing development of the operating mines.
  • MMG shares should continue to decline heading into the ex-rights date. The shares go ex-rights on 11 June, and the rights start trading from 24 June to 2 July (inclusive).

Raspberry Pi IPO Valuation Analysis

By Douglas Kim

  • Raspberry Pi is expected to raise about £157 million in this IPO. The conditional trading for this IPO is expected to be take place on 11 June.
  • We estimate Raspberry Pi to generate sales of US$342.1 million (up 28.7% YoY) and operating profit of US$48.5 million (up 29.3% YoY) in 2024.
  • Our base case valuation of Raspberry Pi is market cap of £772 million or £4 per share (43% higher than the high end of the initial IPO price range). 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Webtoon Entertainment IPO Preview and more

By | Daily Briefs, ECM

In today’s briefing:

  • Webtoon Entertainment IPO Preview
  • Yankuang Energy Placement – Doesn’t Appear Well Flagged Although Deal Size Is Large
  • Pre-IPO QuantumPharm (PHIP Updates) – Some Points Worth the Attention


Webtoon Entertainment IPO Preview

By Douglas Kim

  • Webtoon Entertainment is getting ready to complete its IPO on the NASDAQ exchange in 2H 2024. Webtoon Entertainment is a subsidiary of Naver Corp (035420 KS).
  • Webtoon is seeking to raise as much of US$500 million at a valuation of US$3 billion to US$4 billion.
  • Webtoon Entertainment is one of the largest Korean company related IPOs in 2024. 

Yankuang Energy Placement – Doesn’t Appear Well Flagged Although Deal Size Is Large

By Ethan Aw

  • Yankuang Energy Group (1171 HK) is looking to raise up to US$608m through a primary follow-on, via selling 270m H-shares.
  • The deal is a somewhat large one to digest, at 10.6 days of three month ADV and 2.7% of current mcap.
  • In this note, we will talk about the placement and run the deal through our ECM framework.

Pre-IPO QuantumPharm (PHIP Updates) – Some Points Worth the Attention

By Xinyao (Criss) Wang

  • We have always been concerned about QuantumPharm’s business model. It is relatively difficult for a service provider like QuantumPharm to scale up revenue by just relying on charging service fees.
  • For AI pharmaceutical companies, how to make money is a pain point for entire industry. Just focusing on preclinical stages would limit profitability.We haven’t seen any certainty of achieving breakeven.
  • Increasing competition would bring more challenges for QuantumPharm. Post-investment valuation in 2021 was too expensive.If its future performance falls short of expectations, then sooner or later the valuation will collapse. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars